Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort

Iannaccone, Antonella; Reisch, Beatrix; Mavarani, L.; Oppong, Marvin Darkwah; Mach, Paweł; Schmidt, Börge; Koeninger, Angela; Gellhaus, Alexandra

doi:10.1080/10641955.2022.2066119

Cited by 11 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Elevated sEnd levels were also detected in early-onset PE and HELLP syndrome, showing a strong correlation with serum levels of sFlt-1/PlGF ( 92 , 93 ). Therefore, mean sEnd levels were elevated at delivery in 72 pathological pregnancies (67 pg./mL in PE and 76 pg./mL in HELLP), compared to 10 normal pregnancies (5 pg./mL), but there was no statistically significant difference between PE and HELLP.…”

Section: Differentiating and Diagnosing Pregnancy Related-tmasmentioning

confidence: 89%

Pregnancy as a susceptible state for thrombotic microangiopathies

Frimat,

Gnemmi,

Stichelbout

et al. 2024

Front. Med.

View full text Add to dashboard Cite

Pregnancy and the postpartum period represent phases of heightened vulnerability to thrombotic microangiopathies (TMAs), as evidenced by distinct patterns of pregnancy-specific TMAs (e.g., preeclampsia, HELLP syndrome), as well as a higher incidence of nonspecific TMAs, such as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, during pregnancy. Significant strides have been taken in understanding the underlying mechanisms of these disorders in the past 40 years. This progress has involved the identification of pivotal factors contributing to TMAs, such as the complement system, ADAMTS13, and the soluble VEGF receptor Flt1. Regardless of the specific causal factor (which is not generally unique in relation to the usual multifactorial origin of TMAs), the endothelial cell stands as a central player in the pathophysiology of TMAs. Pregnancy has a major impact on the physiology of the endothelium. Besides to the development of placenta and its vascular consequences, pregnancy modifies the characteristics of the women’s microvascular endothelium and tends to render it more prone to thrombosis. This review aims to delineate the distinct features of pregnancy-related TMAs and explore the contributing mechanisms that lead to this increased susceptibility, particularly influenced by the “gravid endothelium.” Furthermore, we will discuss the potential contribution of histopathological studies in facilitating the etiological diagnosis of pregnancy-related TMAs.

show abstract

Section: Differentiating and Diagnosing Pregnancy Related-tmasmentioning

confidence: 89%

Pregnancy as a susceptible state for thrombotic microangiopathies

Frimat,

Gnemmi,

Stichelbout

et al. 2024

Front. Med.

View full text Add to dashboard Cite

show abstract

“…However, concentrations of sEng were lower in FGR compared with pre-eclampsia pregnancies [ 111 ]. More recent study showed that sEng is strongly correlated with sFlt-1/PlGF ratio with higher concentrations observed in FGR (OR: 2.28, 95% Cl: 1.55–3.4 and 2.38, 95% CI: 1.64–3.44 for sEng and sFlt-1/PlGF, respectively) [ 112 ]. Another study, however, did not find any significant association between maternal concentrations of sEng and time of delivery in pregnancies complicated by FGR [ 113 ].…”

Section: Angiogenic Factorsmentioning

confidence: 99%

Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction

Hong

Kumar

2023

Clinical Science

View full text Add to dashboard Cite

Fetal growth restriction (FGR) leading to low birth weight (LBW) is a major cause of neonatal morbidity and mortality worldwide. Normal placental development involves a series of highly regulated processes involving a multitude of hormones, transcription factors, and cell lineages. Failure to achieve this leads to placental dysfunction and related placental diseases such as pre-clampsia and FGR. Early recognition of at-risk pregnancies is important because careful maternal and fetal surveillance can potentially prevent adverse maternal and perinatal outcomes by judicious pregnancy surveillance and careful timing of birth. Given the association between a variety of circulating maternal biomarkers, adverse pregnancy, and perinatal outcomes, screening tests based on these biomarkers, incorporating maternal characteristics, fetal biophysical or circulatory variables have been developed. However, their clinical utility has yet to be proven. Of the current biomarkers, placental growth factor and soluble fms-like tyrosine kinase 1 appear to have the most promise for placental dysfunction and predictive utility for FGR.

show abstract

“…A number of scientific studies have shown that pre-eclampsia increases not only the level of sflt1 but also the soluble endoglin (sEng) [ 15 , 36 , 122 , 123 , 124 , 125 ]. An increased level of sEng is usually accompanied by, and correlated with, an increased sFlt1/PlGF ratio [ 126 , 127 ]. Iannaccone et al noted that the highest indicators of sFlt-1/PlGF ratio and sEng were observed in HELLP syndrome and EOPE [ 127 ].…”

Section: Sflt1/plgf Ratio and Serum And Urine Biomarkers Of Pregnant ...mentioning

confidence: 99%

“…An increased level of sEng is usually accompanied by, and correlated with, an increased sFlt1/PlGF ratio [ 126 , 127 ]. Iannaccone et al noted that the highest indicators of sFlt-1/PlGF ratio and sEng were observed in HELLP syndrome and EOPE [ 127 ].…”

Section: Sflt1/plgf Ratio and Serum And Urine Biomarkers Of Pregnant ...mentioning

confidence: 99%

Literature Review: The sFlt1/PlGF Ratio and Pregestational Maternal Comorbidities: New Risk Factors to Predict Pre-Eclampsia

Karpova¹,

Dmitrenko²,

Budykina

2023

IJMS

View full text Add to dashboard Cite

One of the main causes of maternal and neonatal morbidity and mortality is pre-eclampsia. It is characterized by a high sFlt1/PlGF ratio, according to prior research. Pregestational diseases in mothers may increase the risk of developing pre-eclampsia. Only a few studies have looked at the connection between maternal comorbidities before conception and the sFlt1/PlGF ratio. The most recent information regarding the association between maternal pregestational diseases and the ratio of sFlt1/PlGF is described in this review. The paper also examines current research suggesting that changes in pregnancy hormones and metabolites are related to a high sFlt1/PlGF ratio. Certain maternal disorders have been found to dramatically raise sFlt-1 and sFlt1/PlGF levels, according to an analysis of the literature. There is still debate about the data on the association between the sFlt1/PlGF ratio and maternal disorders such as HIV, acute coronary syndromes, cardiovascular function in the mother between 19 and 23 weeks of pregnancy, thyroid hormones, diabetes, and cancer. Additional research is needed to confirm these findings.

show abstract

Soluble endoglin versus sFlt-1/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort

Cited by 11 publications

References 39 publications

Pregnancy as a susceptible state for thrombotic microangiopathies

Pregnancy as a susceptible state for thrombotic microangiopathies

Circulating biomarkers associated with placental dysfunction and their utility for predicting fetal growth restriction

Literature Review: The sFlt1/PlGF Ratio and Pregestational Maternal Comorbidities: New Risk Factors to Predict Pre-Eclampsia

Contact Info

Product

Resources

About